Lundbeck and Otsuka further expand their alliance and enter into collaboration for the development and commercialization of Lu AE58054 in development for Alzheimer’s disease
· Clinical phase II data will be presented at the AAIC in Boston in July 2013 · A phase-III program of more than 2,500 patients will commence during 2013 · Lundbeck receives from Otsuka USD 150 million upon signing of the deal · Within the two companies’ global agreement this is the first of the projects that will ultimately involve co-development and co-promotion of three Lundbeck drug candidates H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist